Formycon AG
FYB | FRA
Overview
Corporate Details
- ISIN(s):
- DE000A1EWVY8
- LEI:
- 39120005TZ76GQOY8Z19
- Country:
- Germany
- Address:
- Fraunhoferstraße 15, 82152 Planegg
- Website:
- https://www.formycon.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Formycon is a world-leading, independent developer of high-quality biosimilars, meaning follow-on products to biopharmaceutical medicines already on the market. Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company’s activities span the entire range from technical- pharmaceutical development to clinical trials all the way through to preparation and submission of dossiers for regulatory approval. We develop biosimilar medicines to meet the high standards of the world’s most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia. We will continue to expand our position as a globally operating company in the growth market of biosimilars in line with our growth strategy.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-05 06:30 |
Regulatory News Service
Lucentis biosimilar FYB201/Ranivisio (ranibizumab) approved in Brazil
|
English | 14.5 KB | |
| 2025-05-27 14:30 |
Regulatory News Service
Formycon and Fresenius Kabi announce the commercial launch of FYB202/OtulfiTM, …
|
English | 15.2 KB | |
| 2025-05-19 15:00 |
Regulatory News Service
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB…
|
English | 14.2 KB | |
| 2025-05-12 06:30 |
Regulatory News Service
Formycon reports strong operational performance and financial results for first…
|
English | 25.8 KB | |
| 2025-05-12 00:00 |
Earnings Release
Q1 statement / Q1 financial report 2025
|
English | 208.3 KB | |
| 2025-05-09 15:05 |
General Meeting Notice
Formycon AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.06.2025 …
|
German | 153.5 KB | |
| 2025-05-07 09:37 |
Earnings Release
Formycon invites to conference call on the results of the first quarter of 2025…
|
English | 13.5 KB | |
| 2025-04-14 10:50 |
Regulatory News Service
|
English | 3.7 KB | |
| 2025-03-31 00:00 |
Regulatory News Service
Annual financial report 2024
|
English | 25.0 MB | |
| 2025-03-27 06:30 |
Regulatory News Service
Formycon reports on a successful financial year 2024 with strong operational pr…
|
English | 39.6 KB | |
| 2025-03-24 06:30 |
Regulatory News Service
Formycon invites to conference call on the results of the financial year 2024 a…
|
English | 13.5 KB | |
| 2025-03-04 14:00 |
Regulatory News Service
FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the Unit…
|
English | 16.7 KB | |
| 2025-03-03 14:00 |
Regulatory News Service
FYB202/Otulfi (ustekinumab-aauz), a biosimilar to Stelara, launched in the Unit…
|
English | 16.7 KB | |
| 2025-03-01 11:09 |
Report Publication Announcement
|
English | 4.6 KB | |
| 2025-02-28 11:09 |
Report Publication Announcement
|
English | 4.6 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-21 | Seidl, Dr. Andreas | Board | Buy | None | 4,800.00 EUR |
| 2024-04-29 | Mikulcik, Dr. Marc | Close relation | Buy | None | 48,000.00 EUR |
| 2024-04-24 | Glombitza, Dr. Stefan | Board | Buy | None | 97,444.00 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |